Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Many studies report the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to better estimate the level and distribution of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods: In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to December 31, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. We corrected estimates for imperfect test accuracy with Bayesian measurement error models, conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Results: We identified 968 seroprevalence studies including 9.3 million participants in 74 countries. There were 472 studies (49%) at low or moderate risk of bias. Seroprevalence was low in the general population (median 4.5%, IQR 2.4–8.4%); however, it varied widely in specific populations from low (0.6% perinatal) to high (59% persons in assisted living and long-term care facilities). Median seroprevalence also varied by Global Burden of Disease region, from 0.6% in Southeast Asia, East Asia and Oceania to 19.5% in Sub-Saharan Africa (p<0.001). National studies had lower seroprevalence estimates than regional and local studies (p<0.001). Compared to Caucasian persons, Black persons (prevalence ratio [RR] 3.37, 95% CI 2.64–4.29), Asian persons (RR 2.47, 95% CI 1.96–3.11), Indigenous persons (RR 5.47, 95% CI 1.01–32.6), and multi-racial persons (RR 1.89, 95% CI 1.60–2.24) were more likely to be seropositive. Seroprevalence was higher among people ages 18–64 compared to 65 and over (RR 1.27, 95% CI 1.11–1.45). Health care workers in contact with infected persons had a 2.10 times (95% CI 1.28–3.44) higher risk compared to health care workers without known contact. There was no difference in seroprevalence between sex groups. Seroprevalence estimates from national studies were a median 18.1 times (IQR 5.9–38.7) higher than the corresponding SARS-CoV-2 cumulative incidence, but there was large variation between Global Burden of Disease regions from 6.7 in South Asia to 602.5 in Sub-Saharan Africa. Notable methodological limitations of serosurveys included absent reporting of test information, no statistical correction for demographics or test sensitivity and specificity, use of non-probability sampling and use of non-representative sample frames. Discussion: Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including racial and ethnic minorities, until vaccine-derived herd immunity is achieved. Improvements in serosurvey design and reporting are needed for ongoing monitoring of infection prevalence and the pandemic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, given the known variability in dual human data extraction accuracy (reported rates: 65.8-85.5%) 14-19 , original author-extracted values were not treated as a definitive gold standard”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior research has shown wide variability in the accuracy of dual human extraction, with reported rates ranging from 65.8-85.5% 14-19 .”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For human data extraction, we determined sample size using a McNemar test for sample size approximation. Using an estimated human accuracy of 80% (reported rates: 65.8-85.5%) 14-19 , LLM accuracy of 90%, and 95% confidence, we determined a minimum number of 204 variables per study to be extracted.”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827 · cited 1×
“All meta-analysis and meta-regression were done using the meta package in R [34].”
MethodCochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundMunn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131 · cited 1×
“A modified Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies was used to assess study risk of bias [17].”
MethodBi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,958 · cited 1×
“Our review found that health care workers who had close contact with confirmed COVID19 cases had a higher risk of seropositivity, consistent with previous reports [45].”
ResultRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003346 · Cited by 1,000 · cited 1×
“However, these case counts inevitably underestimate the true cumulative incidence of infection [3] because of limited diagnostic test availability [4], barriers to testing accessibility [5], and asymptomatic infections [6].”
Background
Research works printed but not linked: 2
- American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-COVID Testing [Internet]. 2020 [cited 2021 May 15]. Available from: https://asm.org/Articles/2020/September/Clinical- Microbiology-Supply-Shortage-Collecti-1
- Wolters Kluwer. COVID-19 Tools and Resources for Clinicians: Expert Searches [Internet]. 2020. Avail- able from: https://tools.ovid.com/coronavirus/?utm_source=marketo&utm_medium=email&utm_ campaign=0-v035&utm_term=all%20ovid&mkt_tok=eyJpIjoiWkRRM01qWXlPRFV5TnpKbCIsInQiO iIydVZWOUYyRFJJYlg1ZUR4T29sY0tCMGpWcHBVbnpTQWpLTGZQb0RjbnlidUQ2U3lVekxC WjNrN0U4SkZLOE9sM0lHTUlmdXEzMXJcL0pWQkhhSzdGYU92cXJ1RXZ4T3BMc2tmT1ZFMm h2Z09cL0d1MEh6RnowK2NJMGRUbEZSdGQ0VmpQUmpybkljWEpPVnFDUTdnZnlRUT09In0%3D
Cited by
Items 201–238 of 238
Mwale, S. E., Chisale, M., Chimenya, M., Tandwe, T. N. G., Chapeta, Y., Nkosi, M. M., Nyambalo, B. W., Ngonga, J., Munyenyembe, P., Kayange, W., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1870665/v1
U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022
Hamida, A. B., Charles, M. D., Murrill, C. S., Henao, O. L., & Gallagher, K. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000658
“Early in the pandemic and before the introduction of SARS-CoV-2 vaccines, most seroprevalence survey objectives focused on assessing the true burden of disease to help identify gaps in national public health surveillance systems and identify at-risk populations [11,17,25].”
InfluentialAbdelrahman, M. M., Hemdan, S. B., Farag, R., Eldin, A. N., Khalaf, A., Bakheet, T. M., & Shafik, N. M. (2023) · Egyptian journal of Immunology · doi:10.55133/eji.300104
Alnour, T. M. S., Al‐Amer, O. M., Saeedi, N. H., Shater, A. F., Alsuba, M. A., & Ahmed-Abakur, E. H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283197
Consiglio, E., Freytes, C., Facal, L., Santos, M. J. D., Caffera, M. R., Mozgovoj, M., Robledo, I. C., Pilloff, M., Souto, A. F., & Pedrosa, J. (2023) · Población y Salud en Mesoamérica · doi:10.15517/psm.v21i1.53436
“…1:3,8 respecto de los casos diagnosticados mediante RTqPCR, y una evolución aproximada de unos 8 meses desde el primer caso; valor cercano a la mediana ajustada del 10,6 % de prevalencia en la región (Intercuartil 25 %-75 %: 3,0-46,5 %), estimada mediante un metanálisis (Bobrovitz N. et al., 2021).”
BackgroundMorgan, G., Briollais, L., Clausen, M., Casalino, S., Mighton, C. E., Chowdhary, S., Frangione, E., Fung, C. Y. J., Arnoldo, S., Bearss, E., et al. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110607
Seroprevalence of COVID-19 Antibodies among Patients with Haemophilia
Garg, C. (2022) · Journal of Advanced Research in Medicine · doi:10.24321/2349.7181.202215
Covid-19 in Deutschland und Frankreich
Rissland, J. (2023) · Frankreich-Forum · doi:10.14361/9783839467893-003
Ribeiro, J. A. M., Marinho, L. D. C. S., Fonseca, S. G. C., D’Almeida, J. B., Massignan, C., & Lia, É. N. (2024) · Tempus Actas de Saúde Coletiva · doi:10.18569/tempus.v16i3.3065
Masemo, A., Mwakasungula, S., Kheir, K., Mgina, E. J., Nassor, N. K., Kassim, I., Bakar, B., Salim, K., Mswata, S., Omar, K., et al. (2024) · Advances in Infectious Diseases · doi:10.4236/aid.2024.141004
“%) in individuals in assisted living and long-term care facilities [42], our findings revealed a higher SARS-CoV-2 seroprevalence of 42.9% (n = 102/238) from people who attended markets, followed by students 28.9% (n = 88/304) and health care workers 27.3% (n = 45/165).”
InfluentialRuttoh, V. K., Kipkoech, B., Tonui, R., John, R. O., Mwangi, I. N., Gicho, R. W., Kamau, S. W., Njihia, M. W., Symekher, S. L., Mwanzia, T. M., et al. (2024) · Preprints.org · doi:10.20944/preprints202403.0923.v1
Assessing Seroprevalence of SARS-CoV-2 Antibodies Among US College Students after School ReopeningPreprint
Feeder, S. E., Ratishvili, T., Carlson, B. L., Grill, D. E., Goergen, K. M., Kennedy, R. B., Ovsyannikova, I. G., & Poland, G. A. (2024) · medRxiv · doi:10.1101/2024.04.23.24305972
Correa, A. V., Coronel, N. S., Bayer, A., Aranda, E. F. M., Samudio, M., Giménez-Ayala, A., Santacruz, L., Ojeda, M. L., Espinola, I., & Jorgge, R. (2024) · Revista chilena de infectología · doi:10.4067/s0716-10182024000200239
Rivera, T. J. F., Alcántara, J. A. A., Padilla, A. C., Fuentes, R. F., Machado, L. E., Palma-García, L., Cáceres, P. K. A., Arévalo, A. S. B., Salazar, G. H. S., Pérez, A. P. G., et al. (2024) · Anales de la Facultad de Medicina · doi:10.15381/anales.v85i2.28062
Bolijn, R., Spijkerman, A. M. W., Galenkamp, H., Blokstra, A., Coyer, L., Boyd, A. C., Prins, M., & Stronks, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311196
Manji, K. P., Masemo, A., Das, S., Ali, A. S., Singh, N., Aftab, F., Dutta, A., & Deb, S. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003831
“However, few studies have thoroughly synthesized seroprevalence findings [25,26].”
Subido-Cariño, M. T., Donadel, M., Asi, L. D., Ariola-Ramos, M. S., Arguelles, V. L., Co, S. N., Mahon, G., Fernandez, S., Punzalan, K. A., Sornillo, J. B., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf342
“SARS-CoV-2 seroprevalence surveys provide valuable insight into population-level immunity and are useful tools for program planning and decision-making in public health [13–15].”
Rani, R., Bajos, N., & Counil, É. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1642407 · Cited by 1
“Further, a systematic review and meta-analysis, which included 968 studies from 74 countries, also reported no difference in seroprevalence between genders, globally (31).”
Kaboré, N. F., Ouédraogo, S., Kamga, A. M., Traoré, I. T., Kania, D., Badolo, H., Sanou, G., Koné, A., Yara, M., Kagone, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23505235
Kaboré, N. F., Ouédraogo, S., Kamga, A. M., Traoré, I. T., Kania, D., Badolo, H., Sanou, G., Koné, A., Yara, M., Kagone, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23505229
Hoballah, A., Haidari, R. E., Siblany, G., Abdel‐Sater, F., Mansour, S., Hassan, H., & Abbas, L. A. (2022) · Figshare · doi:10.6084/m9.figshare.18132285
Richard, L., Nisenbaum, R. A., Colwill, K., Mishra, S., Dayam, R. M., Liu, M., Pedersen, C., Gingras, A., & Hwang, S. W. (2024) · Figshare · doi:10.6084/m9.figshare.26672178
Self-citationPuteková, S., Martinkova, J., Uríčková, A., Kober, L., Reichertová, S., Plančíková, D., & Majdán, M. (2023) · Figshare · doi:10.6084/m9.figshare.23258703
Duong, S., Burtniak, J., Gretchen, A., Mai, A., Klassen, P., Wei, Y., Loeppky, C., Shaw, S. Y., Bullard, J., Caeseele, P. G. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24751292
Kaboré, N. F., Ouédraogo, S., Kamga, A. M., Traoré, I. T., Kania, D., Badolo, H., Sanou, G., Koné, A., Yara, M., Kagone, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23505232
Kaboré, N. F., Ouédraogo, S., Kamga, A. M., Traoré, I. T., Kania, D., Badolo, H., Sanou, G., Koné, A., Yara, M., Kagone, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23505238
Ghoroubi, N., Khlat, M., & Counil, É. (2025) · Journal of Migration and Health · doi:10.1016/j.jmh.2025.100392
Santos, A. C. (2021) · Arca - Repositório Institucional da Fiocruz
Momou, K. J., Touré, F. S., Diané, B., Anoh, A. E., Monemo, P., Tomczyk, S. M., Bcheraoui, C. E., Akoua-Koffi, C. G., & Boone, I. (2026) · Research Square · doi:10.21203/rs.3.rs-8702917/v1
Work-Related Exposures Mediate Occupational Class Disparities in SARS-CoV-2 Infection in France
Counil, É., Ghoroubi, N., & Khlat, M. (2026) · International Journal of Public Health · doi:10.3389/ijph.2026.1608670
“Although older adults faced the highest risk for COVID-19 complications [8] and mortality [9], working-age adults were among the most infected [10], making it crucial to examine the socio-occupational disparities in infection risk within this group.”
Morgan, G. (2023) · TSpace (University of Toronto)
Houatthongkham, S., Xangsayarath, P., Khamphaphongphane, B., Inthaphatha, S., Aoki, A., Nishino, K., & Yamamoto, E. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13543-9
“Limited testing capacity, asymptomatic infections, and barriers to healthcare access may have resulted in underreporting, as observed in many LMICs [29, 30].”
Agyei, G., El‐Duah, P., Dumevi, R. M., Muzeniek, T., Aryeetey, S. N. A., Fogang, B. A. N., Gmanyami, J. M., Sylverken, A. A., Adu‐Sarkodie, Y., Phillips, R. O., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348281
Sulcebe, G., Kurti-Prifti, M., Shyti, E., Seferi-Qendro, I., Ylli, A., & Perry, M. J. (2026) · Albanian Journal of Natural and Technical Sciences · doi:10.67537/ajnts3101014
Sulcebe, G., Shyti, E., Kurti-Prifti, M., Seferi-Qendro, I., Ylli, A., & Perry, M. J. (2024) · Albanian Journal of Natural and Technical Sciences · doi:10.67537/ajnts2902013
Beyond the blood: Tissue-resident immunity shapes SARS-CoV-2 vaccine antibody responsesPreprint
Schröter, J., van Dorp, C. H., Davis‐Porada, J., Teijaro, J. R., Färber, D. L., & Yates, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.23.740375
Feredj, E., Zhang, Q., Bastard, P., Casanova, J., & Cobat, A. (2026) · medRxiv · doi:10.64898/2026.08.06.26359907
Warszawski, J., Bagein, G., Deroyon, T., Costemalle, V., Boulch, A., Sanon, H., Sillar, P., Rahib, D., Bajos, N., & Epicov, L. (2026) · Population · doi:10.3917/popu.2601.0013 · Cited by 3
Metadata
- Authors
- Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., Rahim, H., Ilincic, N., Segal, M., Duarte, N., Van Wyk, J., Yan, T., Atmaja, A., Rocco, S., Joseph, A., Penny, L., Clifton, D. A., Williamson, T., Yansouni, C. P., Evans, T. G., Chevrier, J., Papenburg, J., & Cheng, M. P.
- Affiliations
- University of Calgary (CA)
- University of Oxford (GB)
- McGill University (CA)
- University of Toronto (CA)
- University of Waterloo (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Bobrovitz, Niklas
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-23
- Volume
- 16
- Issue
- 6
- Pages
- e0252617
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8221784
- OpenAlex
- W3173470851
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 33 · 2023: 66 · 2022: 81 · 2021: 43
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Public Health Agency of Canada via the COVID-19 Immunity Task Force
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulins, seroepidemiology, racial and ethnic disparities, indigenous peoples, long-term care facilities, perinatal infection, cumulative incidence, public health decision-making, infection risk factors, high-risk groups, SARS-CoV-2 variants
- MeSH terms
- COVID-19, COVID-19 Serological Testing, Adolescent, Adult, Aged, Antibodies, Viral, Child, Health Personnel, Humans, Middle Aged, Sensitivity and Specificity, Incidence, Seroepidemiologic Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.